A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Stopped At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.
Conditions
- Triple Negative Breast Cancer
- Endometrial Cancer
- Solid Tumor, Unspecified, Adult
- Colorectal Cancer
Interventions
- DRUG: Fruquintinib
- DRUG: Tislelizumab
Sponsor
Hutchmed
Collaborators